A Baxter International Inc. product for use in renal replacement therapy has received approval from the U.S. Food and Drug Administration.
Baxter’s Phoxillum is designed to correct electrolyte and acid-base imbalances for patients undergoing continuous renal replacement therapy. The Deerfield pharmaceutical and medical device maker said it expects the product be available in the U.S. beginning in the second quarter.
“The approval of Phoxillum allows us to offer healthcare providers additional options in managing critically ill acute kidney injury patients treated with CRRT,” said Bruce Culleton, a Baxter vice president and head of its renal therapeutic area.
